RBC Capital Reiterates Outperform on Bio-Rad Laboratories, Maintains $401 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Conor McNamara has reiterated an Outperform rating on Bio-Rad Laboratories (NYSE:BIO) and maintained a price target of $401.
August 16, 2024 | 3:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated an Outperform rating on Bio-Rad Laboratories and maintained a price target of $401.
The reiteration of an Outperform rating and a maintained price target of $401 by RBC Capital is a positive signal for investors, suggesting confidence in Bio-Rad Laboratories' future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100